Table 1

Baseline cognitive, neuropsychological and ADL function according to follow-up groups
Groups n MMSE ± SD* ADAS-cog ± SD* CDT** ± SD* BI§ ± SD* NPI‡ ± SD*
Municipality
Stimulation 103 22.9 ± 4.6 18.9 ± 8.7 2.85 ± 1.2 6.08 ± 9·6 18.6 ± 2.6
Standard care 77 23.5 ± 4.3 17.1 ± 7.0 2.84 ± 1.2 8.48 ± 10·5 18.6 ± 3.2
p-value 0.34 0.22 0.96 0.12 0.995
Drug
Donepezil 90 23.2 ± 4.2 18.6 ± 7.7 2.86 ± 1.1 7.48 ± 11·4 18.9 ± 2.1
Placebo 90 23.1 ± 4.8 17.9 ± 8.4 2.84 ± 1.2 6.70 ± 8·9 18.4 ± 3.4
p-value 0.83 0.55 0.95 0.61 0.29
Combination
Donepezil 53 22.9 ± 4.5 19.2 ± 8.7 2.92 ± 1.1 6.29 ± 11·3 18.7 ± 2.3
+ stimulation
Placebo
+ Standard care 40 23.3 ± 4.9 17.2 ± 8.0 2.93 ± 1.2 7.76 ± 10·4 18.1 ± 4.0
p-value 0.64 0.24 0.998 0.53 0.45
Head to head
Stimulation therapy 50 22.9 ± 4.7 18.5 ± 8.7 2.78 ± 1.3 5.85 ± 7·4 18.6 ± 2.8
Donepezil 37 23.7 ± 3.7 17.6 ± 5.8 2.76 ± 1.3 9.29 ± 10·8 19.1 ± 1.8
p-value 0.36 0.62 0.93 0.09 0.31

*Mean values ± Standard deviation. **CDT = Clock Drawing Test scale 0–4 (4 best function) §BI = Barthel Index, scale 0–20 (20 best function). ‡ NPI = Neuropsychiatric Inventory, Scale 0–144 (144 worst case).

Andersen et al.

Andersen et al. BMC Neurology 2012 12:59   doi:10.1186/1471-2377-12-59

Open Data